In Vivo: Lapaquistat acetate (diet supplemented; 100 or 200?mg/kg; 32 weeks) decreases plasma cholesterol and triglyceride levels. It?delays progression of coronary atherosclerosis and changes coronary atheromatous plaques from unstable, macrophage/lipid accumulation-rich, lesions to stable fibromuscular lesions in vivo.